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Background Peri-stent coronary evaginations may disturb ﬂow and have been proposed as possible risk factor for late stent throm-
bosis. We describe incidence, predictors, and possible mechanisms of coronary evaginations 12 months after implant-
ation of bioresorbable vascular scaffolds (BVS).
Methods
and results
One hundred and two BVS implanted in 90 patients (age 63+ 13 years, 71 males, 14 diabetics) were analysed with
angiography and optical coherence tomography (OCT) 12 months after implantation. Evaginations were identiﬁed
as any hollow in the luminal vessel contour between well-apposed struts and were classiﬁed as major when extending
≥3 mm with a depth ≥10% of the BVS diameter. Fifty-ﬁve (54%) of the BVS (50(56%) of the patients) had at least one
evagination (6.1+ 6.2 evaginations per BVS), with a mean volume of 1.9+ 1.9 mm3. Major evaginations were only
found in one patient, and in-BVS aneurysms in three patients (4BVS). The presence of evaginations was strongly asso-
ciated with that of malapposition (P ¼ 0.003) and strut fractures (P ¼ 0.01). No association could be shown between
the presence and volume of the evaginations and any clinical variable or the presence of uncovered struts (P. 0.5).
Peri-strut low-intensity areas (PSLIA) were present in 29 (53%) of the BVS with evaginations and 12 (26%) of those
without (P ¼ 0.0049); their presence was independently associated with the presence, the number (P, 0.003) and
volume of the evaginations (P ¼ 0.004) and with that of strut fracture.
Conclusions Optical coherence tomography-detected evaginations are relatively common after BVS implantation, but, as for mod-
ern drug-eluting metallic stents, major evaginations are very rare. Optical coherence tomography evidence of immature
neointima and strut fractures were associated with more severe development of evaginations.
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Introduction
Late acquired coronary evaginations—also termed parasailing phe-
nomenon or cauliﬂower’s effect—are optical coherence tomog-
raphy (OCT) ﬁndings frequently described following implantation
of ﬁrst-generation drug-eluting stents (DES). In this setting, evagina-
tions have been proposed to represent the manifestation of patho-
logical vessel healing and have been associated with the presence of
uncovered or fractured struts.1–4 Together with the resulting ﬂow
disturbances, they have been hypothesized as possible risk factors
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which should be cited to refer to this work.
for stent thrombosis.5–9 Notably, the incidence of coronary evagi-
nations appears to be signiﬁcantly lower after implantation of
newer-generation stents,1 an observation that ﬁts well with the low-
er incidence of in-stent thrombosis reported following implantation
of these devices.10–12
The everolimus-eluting bioresorbable vascular scaffold (BVS) has
been introduced into clinical practice in May 2012 with the hope
of overcoming late-occurring complications of DES. While early
studies are promising,13 – 15 some concerns of an unexpectedly
high incidence of scaffold thrombosis were recently raised.13,16
Accordingly, recent publications reported cases of inadequate
vessel healing after BVS implantation, with possible evagination
development.16,17
We set out to explore the presence, size, predictors, and possible
mechanisms of coronary evagination formation 12 months after BVS
implantation.
Methods
Study design and population
Absorb BVS (Abbott Vascular, USA) are balloon-expandable scaffolds
made with semicrystalline polylactide and eluting the newer-generation
drug everolimus. Their strut thickness is 150 mm, similar to the ﬁrst-
generation DES.18 The present report includes all consecutive patients
who received at least one BVS and underwent coronary angiogram with
OCT study at 12-month follow-up (an invasive follow-up was recom-
mended in the ﬁrst 150 patients given the novelty of this therapy and
scarcity of data available in real-life settings). Implantation was per-
formed using standard techniques and following instructions for use,
dual antiplatelet therapy was recommended for 12 months. Baseline
clinical characteristics, angiographic and OCT data were collected in
anonymised way. Patients gave written informed consent for the collec-
tion of data within the framework of the MICAT Registry (EC
837.123.13;8808-F;NCT02180178). There was no industry involvement
in the design, conduct, or analysis of the study. No patient was included
in any industry-sponsored trial.
Optical coherence tomography
See also Supplementary material online, Methods.
‘Evaginations’ were deﬁned as any outwards protrusion in the luminal
vessel contour between well-apposed stent struts (Figure 1A). Evagi-
nations were considered major when extending .3 mm with a
depth.10% of the stent diameter.
‘Coronary aneurysms’ were deﬁned as an in-scaffold diameter
.1.5-times the reference vessel diameter at follow-up (Figure 2A).
‘Peri-strut low-intensity areas (PSLIA)’ were deﬁned as homogenous
areas with low-signal attenuation around struts characterized by an in-
tensity 30% lower than that of the surrounding tissue (Figure 3A and B).
‘Strut fracture’ was classiﬁed in grades as described in Supplementary
material online.
Peri-stent staining and quantitative coronary
analysis
‘Peri-stent contrast staining (PSS)’ was deﬁned as evidence of contrast
staining outside of the vessel contour (Figure 3C). Bioresorbable vascu-
lar scaffolds undersizing and oversizing were deﬁned as (respectively):
proximal reference diameter/BVS nominal size .1.2 or ,0.8. Deﬁni-
tions are described in more detail in Supplementary material online,
Methods.
Vasomotor function
Quantitative coronary analysis was performed in the scaffold segment in
random order by staff not aware of the temporal sequence of the
images. Endothelium-dependent and -independent vasomotion were
studied as previously published.19
Follow-up
Clinical follow-up data focused on the incidence of thrombosis were
collected from all patients during clinical visits or per telephone using
standardized questionnaires. Events were adjudicated by one investiga-
tor and monitored by another one.
Statistical analysis
See Supplementary material online, Methods.
Results
The study enrolled 90 patients who underwent BVS implantation
and elective 12 months control angiography with OCT. Of the ﬁrst
150 patients who received BVS in our institution, 23 underwent
Figure 1 (A) Example of optical coherence tomography cross section with evagination. Measures included the area (taken from the abluminal
margin of the line connecting the middle points of the most continuous struts), depth, and transversal length. An example of measures is reported
in white. Interestingly (B–D), this patient also developed evaginations and malapposition (M) at the level of an everolimus-eluting metal stent. Ar
marks a typical optical coherence tomography artefact.
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coronary angiography at earlier time points (without systematic
OCT). Five patients died before 12 months (among these one sud-
den death on Day 18 after PCI in a patient with severe three-vessel
disease, cardiogenic shock, and a history of drug addiction). Finally,
four patients underwent elective angiography without OCT at 12
months patient and lesion characteristics are detailed in Table 1.
Mean age was 63+ 13 years, 79% were male, 16% diabetics, 44%
smokers, 74% had arterial hypertension, and 30% hypercholesterol-
aemia. The indication at index procedure was an acute coronary
syndrome in 66% of the cases. At the time of the invasive control,
angina(-like) symptoms were present in 45 patients (39%). In total,
102 BVS underwent OCT control (1.1+0.5 BVS per patient).
Figure 2 (A–C) A case of coronary artery aneurysm at the level of the proximal left anterior descending in a 44-year-old woman who presented
with ST-elevation myocardial infarction and received a 3 × 18 mm bioresorbable vascular scaffolds in the proximal left anterior descending. Of
note, the aneurysmwas not present 1-month after implantation, and a similar aneurysmatic reaction was present in another bioresorbable vascular
scaffolds implanted in the same patient in the right coronary artery. (B) Computed tomography scan of the proximal left anterior descending re-
vealing an6 mm aneurysm 18months after implantation. (C) Evidence of evaginations (Ev) andmalapposition (M) in the same patient. This case is
described in detail in Ref. 31 (D–F) late acquired small saccular aneurysm in the mid right coronary artery in a 75-year-old patient who received a
3 × 18 mm in the setting of unstable angina. 12-months optical coherence tomography at this level demonstrated (E) collapse of the struts, which
were otherwise well apposed in the proximal and distal segments (longitudinal view, white circle). 3D reconstruction conﬁrmed the aneurysm and
the collapse of the struts (arrows and dashed circle). (G– I) the last case of aneurysm was observed in a 69-year-old man who received a
3 × 18 mm bioresorbable vascular scaffolds in the proximal left anterior descending. It is possible that a trauma caused by high-pressure post-
dilation with a 3.5 mm balloon might have triggered the aneurysmatic process in this case. (G) Immediate result showing overexpansion of the
bioresorbable vascular scaffolds (dashed line); (H) 12-month angiography showing aneurysmatic evolution of the lesion. (I) Optical coherence
tomography demonstrating a ﬁbrolipidic plaque protrusion (1 o’clock) which prevented the deployment of the scaffold and required high-pressure




From a total of 102 BVS studied, 55 BVS (54%) in 50 patients (56%)
had ≥1 evagination. These patients represent the ‘evagination
group’. Major evaginations were found in only one BVS. Four (4%)
BVS in three patients (3%) showed aneurysms (Figure 2), in one
case likely provoked by mechanical trauma at implantation. The
mean number of evaginations was 6.1+ 6.2 per BVS and 6.7+
8.7 per patient, with a mean total volume of 1.9+ 1.9 mm3 per
BVS and 2.1+ 2.6 mm3 per patient. The volume of the evaginations
is presented in Supplementary material online, Figure S2 as % of the
total volume of the corresponding BVS. In 56% of the BVS, the total
volume of the evaginations was lower than 1% of the BVS volume. In
2 (4%) BVS, the total evaginations volume exceeded 5% of the BVS
volume.
Angiographic and optical coherence
tomography ﬁndings at follow-up
Peri-stent contrast staining was found in nine BVS segments (18%)
(all in the evagination group). Peri-stent contrast staining was asso-
ciated with an increased number and volume of evaginations (P ¼
0.002 and P ¼ 0.0001, respectively).
The RVD values of the segments which presented evaginations
were consistently larger when compared with those of the seg-
ments that did not show evaginations (Supplementary material on-
line, Table S1). In contrast, there was no difference in MLD and late
lumen loss. Vascular diameter changes at QCA were different
between the evagination group (+0.03+ 0.48 mm) and the
non-evagination group (20.13+ 0.39 mm, P ¼ 0.06). A larger
RVD at 12 months than at index was present in 24 (48%) of the
evagination group and 16 (40%) of the non-evagination group
(P ¼ 0.43). The presence of PSLIA was not associated with changes
in RVD (P ¼ 0.22).
The OCT characteristics of the BVS are presented in Supplemen-
tary material online, Table S2. At 12-months, all lumen and BVSmea-
sures were signiﬁcantly larger in the evaginations group. Measures of
malapposition were also larger in this group. Peri-strut low-intensity
areas was more frequent in BVS with evaginations. In contrast,
eccentricity and uncovered struts were not associated with
evaginations.
Evaginations, strut fractures, and
peri-strut low-intensity areas
Table 2 describes the characteristics of the evaginations based on
the presence of PSLIA. Peri-strut low-intensity areas was present
in 29(53%) of the BVS with evaginations and 12 (26%) of those with-
out (P ¼ 0.005). Peri-strut low-intensity areas was present at the le-
vel of the evagination in 13(24%) BVS. Shortly, PSLIA was
systematically associated with all measures expressing the severity
of the evaginations. As well, PSLIAwas associated with the presence
(P ¼ 0.005) of malapposition. The presence of PSLIA at the trough
of the evagination (Figure 3B) further identiﬁed a subset of patients
with more (10.2+ 7.1 vs. 4.8+ 5.4, P ¼ 0.005) and larger (P ¼
3.2+ 2.2 vs. 1.5+ 1.6 mm3, P ¼ 0.0004) evaginations. Conversely,
PSLIA was not associated with neointima thickness (P ¼ 0.70) or
uncovered struts (P ¼ 0.85).
The incidence and distribution of the fractures is described in
Supplementary material online, Table S3. Strut fracture/misalign-
ments were present in 30% of the BVS, and their rate and com-
plexity were higher in the evaginations group (55% of the BVS
with evaginations and 17% of the BVS without evaginations, P ¼
0.013). Fractures/misalignments were also associated with PSLIA
(P ¼ 0.021).
Figure 3 Peri-strut low-intensity area (marked with asterisk) was deﬁned as a region of low intensity and low attenuation in the proximity of
bioresorbable vascular scaffolds struts. The presence of peri-strut low-intensity area (A) and that of peri-strut low-intensity area at the level of the
evaginations (B) was recorded. (C) Evidence of peri-stent staining in the proximal right coronary artery in a 47-year-old female treated for inferior
STEMI. Optical coherence tomography (D and E) revealed the presence of evaginations which were also visible in 3D and longitudinal reconstruc-
tions (white arrows).
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Associations with patient and procedural
characteristics
Longer BVS and undersizing, as well as PSLIA, weremore frequent in
the evaginations group (Table 1). In univariate analysis, none of the
traditional risk factors were associated with the presence of evagi-
nations (Table 3). Of the procedural characteristics, the use of post-
dilation at the time of BVS implantation, the use of longer stents,
undersizing, and PSLIA were all associated with evaginations. In
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Table 1 Clinical and procedural characteristics
All patients (n5 90) Evaginations present (n 5 50) No evagination (n5 40) P-value
Patient characteristics (per patient analysis)
Male sex, n (%) 71 (79%) 39 (78%) 32 (80%) 0.053
Age 63+13 64+24 61+12 0.176
Hypertension 67 (74%) 38 (76%) 29 (73%) 0.574
Hyperlipidaemia 27 (30%) 14 (29%) 15 (33%) 0.616
Diabetes 14 (16%) 6 (12%) 8 (20%) 0.414
Smoking 40 (44%) 24 (48%) 16 (40%) 0.461
Previous revascularization 22 (24%) 13 (26%) 9 (23%) 0.514
Clinical presentation
Stable angina 16 (18%) 9 (18%) 7 (18%) 0.80
Unstable angina 13 (14%) 7 (14%) 6 (15%)
NSTEMI 27 (30%) 16 (32%) 11 (28%)
STEMI 32 (35%) 16 (32%) 16 (40%)
Glomerular ﬁltration rate (mL/min) 87+22 86+39 88+16 0.591
LVEF (%) 52+8 52+15 52+9 0.214
Multi-vessel disease 10 (11%) 7 (14%) 3 (8%) 0.401
DAPT type 0.407
Clopidogrel 30 (33%) 17 (31%) 13 (34%)
Prasugrel 43 (48%) 23 (48%) 20 (50%)
Ticagrelor 17 (19%) 10 (19%) 7 (16%)
Number of implanted BVS 1.1+0.5 1.1+0.5 1.2+0.5 0.617
Total BVS length (mm) 20.64+9.6 21.1+10.5 20.1+8.3 0.631
Total BVS surface (cm2) 2.23+1.16 2.25+1.19 2.20+1.14 0.839
n ¼ 102 n ¼ 55 n ¼ 47
Procedural and scaffold characteristics (per scaffold analysis)
Vessel treated
LAD 39 (38%) 19 (35%) 20 (43%) 0.582
RCX 26 (25%) 14 (25%) 12 (26%)
RCA 38 (37%) 23 (42%) 15 (32%)
ACC/AHA type B2/C 43 (42%) 30 (55%) 13 (28%) 0.714
BVS diameter 3.07+0.34 3.1+0.4 3.0+0.3 0.398
BVS length 18.9+7.44 19.8+4.9 17.9+3.4 0.024
BVS outer surface (cm2) 0.57+0.13 0.60+0.15 0.53+0.08 0.008
Implantation pressure 13.7+1.8 13.7+2.0 13.7+1.6 0.888
Post-dilation 17 (17%) 13 (28%) 4 (9%) 0.061
Ballon/artery ratio 1.1+0.3 1.0+02 1.1+0.3 0.128
Undersizing (at index) 19 (19%) 15 (27%) 4 (9%) 0.021
Undersizing (at 12-months) 13 (13%) 11 (20%) 2 (4%) 0.019
Oversizing (at index) 13 (13%) 7 (13%) 6 (13%) 1.000
Oversizing (at 12 months) 11 (11%) 4 (7%) 7 (15%) 0.338
Maximum footprint 36+7 35+10 36+6 0.475
PSLIA at 12-months 37 (36%) 26 (47%) 11 (23%) 0.022
Patients are divided based on the optical coherence tomography ﬁnding of evaginations at the 12 months control.
BVS, bioresorbable vascular scaffold; (N)STEMI, (non)ST-elevation myocardial infarction; DAPT, dual antiplatelet therapy; LAD, left anterior descending; RCX, circumﬂex; RCA,
right coronary artery; PSLIA, peri-stent low-intensity area; ACC/AHA, American College of Cardiology/American Heart Association.
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multivariable analysis, the presence of PSLIA remained associated
with evaginations; BVS outer surface, undersizing, and post-dilation
showed a trend in this direction.
Endothelium-dependent and
-independent responses
Acetylcholine and nitroglycerin responses were studied in 21 (38%)
of the BVS with evaginations and 29 (62%, P ¼ 0.02) of those with-
out evaginations. A vasodilation was observed in 10 (48%) of the
BVS with evaginations and 13 (46%) of those without (P ¼ 1.0).
A vasoconstriction was observed in, respectively, 10(48%) and
7 (25%), P ¼ 0.13. A vasodilation in response to intracoronary nitro-
glycerin was more frequent in the evaginations group (61 vs. 29%,
P ¼ 0.03).
Follow-up
Data on the incidence of in-BVS thrombosis were available from all
patients at a mean follow-up of 780+122 days after index implant-
ation. During this period, two patients included in the present data-
base developed in-BVS thrombosis. In one case (late thrombosis
349 days after implantation), evidence of evaginations, malapposi-
tion, and uncovered struts associated with PSLIA was present at
OCT (Figure 3). In the other case, in which thrombosis occurred
at 562 days, there was evidence of severe malapposition without
PSLIA or evaginations at 12 months.
Discussion
In-stent coronary evaginations and late malapposition are occasion-
ally found after percutaneous coronary interventions. While from a
merely mechanical perspective undersizing or vascular injury at the
time of implantation may play a role,20 an association with localized
hypersensitivity reactions and chronic inﬂammation has also been
proposed,21 even though the speciﬁc stent component (metal, poly-
mer, eluted drug) responsible for these reactions has not been
identiﬁed. Importantly, the incidence of evaginations appears to be
lower with newer-generation DES, which are characterized by dif-
ferent polymers, different drugs, and thinner struts.1 Whatever
the mechanism, evaginations, malapposition, and aneurysms may
disrupt the laminarity of ﬂow, and their presence, particularly
when associated with that of uncovered or fractured struts, or
with evidence of vascular inﬂammation, has been associated with
late in-stent thrombosis.20,22
Summary of the present ﬁndings
Incidence and clinical predictors of
evaginations
Although the presence of small evaginations was very frequent,
ﬁndings of major evaginations were, in line with previous reports
on modern generation DES,1 rare. Evaginations appear to be in a
continuum with malapposition (Figure 4). None of the clinical
and procedural characteristics was formally associated with the
presence of evaginations at 12 months, but vessels in which evagi-
nations were present were consistently larger at QCA at index and
even more so 12 months after implantation. Coupled with the ab-
sence of differences in the size of the BVS implanted between the
two groups, this ﬁnding suggests that undersizing at the time of im-
plantation and/or vessel dilation thereafter may play a mechanistic
role Figure 5).
Association with optical coherence
tomography evidence suggestive of
immature neointima
The intensity of the OCT signal has been previously shown to
correlate with the histologic nature of the tissues studied.23,24
Optical coherence tomography has been demonstrated to be
able to OCT-ﬁndings of PSLIA have been associated with hist-
ology sections richer in elastic ﬁbres and inﬂammatory cells and
macrophages as well as spotty ﬁbrin deposition and relatively
poorer in smooth muscle cells and proteoglycans/collagen.25 In
the present cohort, this OCT ﬁnding correlated positively with
the size and number of the evaginations. Importantly, PSLIA at
12 months was the only predictor that remained associated
with the presence of evaginations in multivariable analysis. As
well, the presence of PSLIA at the level of the evaginations further
identiﬁed a subgroup of BVS in which these lesions were more
pronounced. Although vasomotor function data were incom-
plete, in line with the histological correlates of PSLIA, a trend to-
wards more frequent paradoxical vasoconstriction in response to
acetylcholine, compatible with the presence of endothelial dys-
function, was shown. As well, the more effective vasodilation in
response to nitroglycerin might reﬂect an impaired resting pro-
duction of endothelial nitric oxide associated with the presence
of evaginations.26 Finally, the presence of strut fractures was
strongly associated with PSLIA and evaginations/malapposed
struts. Although a cross-sectional approach does not allow con-
clusions regarding causality, one might hypothesize that this
ﬁnding might be involved in the pathogenesis of PSLIA and
evaginations.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Optical coherence tomography
characteristics of the evaginations classiﬁed based on








9 [6.8–11.8] 3 [2–5] 0.003
Total volume 2.3+2.4 1.4+1.1 0.004




with depth .10% of
BVS diameter
9.4+6.3 4.1+3.9 0.001
Maximum length in mm 0.8+0.6 0.4+0.2 0.009
% of lumen volume 2.1+1.3 1.1+1.2 0.007
PSLIA, peri-strut low-intensity area.
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Limitations
The following shortcomings have to be taken in consideration when
interpreting the results of the present study. First, it is a single-
centre, observational trial with limited size; all analysis was per-
formed on-site and not in an independent core laboratory. Second,
the analysis was limited to BVS with no direct comparator. Further,
the inclusion criterium (OCT at 12 months) might have resulted in
an inclusion bias. The elective nature of the 12-months controls,
however, partially addresses this bias. It also needs to be acknowl-
edged that there is no histopathological analysis; however, a number
of lines of evidence support the concept that PSLIA truly reﬂects im-
mature neointima and/or oedema as well as deposition of ﬁbrin and
extracellular matrix, as demonstrated by ﬁndings from animal and
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Table 3 Univariate and multivariable analysis of the associations of evaginations
HR (5–95% CI) P-value HR (5–95% CI) P-value
Patient characteristics (per patient analysis)
Male sex, n 0.98 (0.34–2.76) 0.962
Age 1.02 (0.99–1.06) 0.176
Hypertension 1.31 (0.5–3.44) 0.583
Hyperlipidaemia 0.83 (0.34–2.06) 0.689
Diabetes 0.56 (0.18–1.77) 0.322
Smoking 1.44 (0.62–3.35) 0.398
Previous revascularization 1.24 (0.47–3.3) 0.661
Clinical presentation
Stable angina 1.06 (0.356–3.16) 0.916
Unstable angina 0.97 (0.3–3.15) 0.956
NSTEMI 1.23 (0.51– 3.19) 0.599
STEMI 0.73 (0.31–1.73) 0.473
Glomerular ﬁltration rate 0.99 (0.99–1.01) 0.587
LVEF 0.96 (0.89–1.03) 0.216
Multi-vessel disease 2.06 (0.55–8.53) 0.321




Procedural characteristics (per patient analysis)
Number of implanted BVS 0.80 (0.34–1.90) 0.616
Total BVS length 1.01 (0.97–1.06) 0.631
Total BVS surface 1.04 (0.72–1.50) 0.841
Vessel treated
LAD 0.71 (0.32–1.59) 0.412
RCX 1.0 (0.41–2.45) 0.991
RCA 1.53 (0.68–3.46) 0.302
ACC/AHA type B2/C 0.8 (0.36–1.74) 0.574
Procedural and scaffold characteristics (per scaffold analysis)
BVS diameter 1.65 (0.52–5.26) 0.394
BVS length 1.12 (1.01–1.24) 0.029
BVS outer surface 120.91 (2.66–5503.55) 0.014 58.48 (0.94–3628.85) 0.053
Implantation pressure 0.98 (0.79–1.22) 0.891
Post-dilation 3.33 (1.00–11.03) 0.049 3.63 (0.99–13.26) 0.051
Ballon/artery ratio 0.18 (0.03–1.04) 0.055
Undersizing (at index) 4.13 (1.26–13.52) 0.019 4.59 (0.90–23.37) 0.067
Undersizing (at 12 months) 5.75 (1.21–27.48) 0.028
Oversizing (at index) 0.85 (0.26–2.85) 0.801
Oversizing (at 12 months) 0.4482 (0.12–1.64) 0.225
Maximum footprint 0.93 (0.87–1.0) 0.472
PSLIA at 12 months 2.85 (1.21–6.74) 0.017 3.39 (1.33–8.62) 0.01
7
Figure 4 Sequential optical coherence tomography frames showing the continuum between evaginations and malpposition. Evaginations are
marked in light blue and the malapposition (left) in red. From proximal to distal, the ﬁrst three slides from right show the evolution of an evagin-
ation. In the fourth section, two malapposed scaffold struts appear, which reclassify this lesion to malapposition. In contrast, the lesion at 6 o’clock
does not contain malapposed struts. This sequence emphasized the importance of frame-by-frame analysis.
Figure 5 (A–G) and Video 1: 2D and 3D images of evaginations (Ev) and malappositions (M). (H–K): 2D and 3D images of a patient with well-
apposed, covered, embedded (Em), and non-embedded (nEm) struts and no evidence of strut discontinuity (Supplementarymaterial online, Video S2).
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human autopsy studies.25,27 Vasomotor function studies were only
performed in a limited number of subjects; in particular, acetylcho-
line was not administered in subjects with more severe evidence of
atherosclerosis and/or evaginations/aneurysms, therefore causing a
bias that would have reduced the differences (if any) between
groups. The impact of severe evaginations/aneurysms/malapposi-
tions remains unclear. Prospective studies would however require
very large cohorts of patients in whom no action (e.g. prolongation
of antiplatelet therapy) is taken. Finally, OCT was performed only
once, and we cannot conclude regarding the progression of evagina-
tions/malapposition areas over time and the time of their ap-
pearance. In a recent case report, evidence of formation and
subsequent receding of a peri-scaffold aneurysm has also been
reported.28 The effect of pulsatile stretch and ﬂow-dependent dila-
tion at the time of scaffold resorption remains to be tested.
Conclusions
Anatomical abnormalities such as aneurysms, malappositions, and
evaginations may disturb the laminarity of ﬂow and have been pro-
posed as a possible mechanisms of late stent thrombosis.20,29,30 In
our cohort, incidence and severity of coronary evaginations follow-
ing BVS implantation were similar to those previously reported for
second-generation DES. Undersizing at the time of implantation was
a possible mechanism of evaginations; further, strut fracture and im-
mature neointima might be associated with the presence and sever-
ity of evaginations (and malapposition) in a small but relevant
subgroup of patients. The implications of these abnormalities, and
possible interventions, will need further investigation.
Supplementary material
Supplementary Material is available at European Heart Journal online.
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